Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
Lancet
; 391(10120): 563-571, 2018 02 10.
Article
in En
| MEDLINE
| ID: mdl-29217375
Full text:
1
Database:
MEDLINE
Main subject:
Viral Vaccines
/
Antibodies, Neutralizing
/
Zika Virus
/
Antibodies, Viral
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Year:
2018
Type:
Article